Immix Biopharma, Inc. $IMMX Shares Acquired by Sei Investments Co.

Sei Investments Co. boosted its position in Immix Biopharma, Inc. (NASDAQ:IMMX) by 100.0% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 147,140 shares of the company’s stock after purchasing an additional 73,570 shares during the period. Sei Investments Co. owned about 0.27% of Immix Biopharma worth $1,340,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of IMMX. Allworth Financial LP purchased a new stake in Immix Biopharma during the fourth quarter worth $30,000. Mathes Company Inc. purchased a new position in shares of Immix Biopharma in the fourth quarter valued at $56,000. Balyasny Asset Management L.P. purchased a new position in shares of Immix Biopharma in the fourth quarter valued at $67,000. Kera Capital Partners Inc. acquired a new position in shares of Immix Biopharma during the 4th quarter worth $68,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Immix Biopharma during the 4th quarter worth $112,000. 11.26% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on IMMX. Weiss Ratings reissued a “sell (d-)” rating on shares of Immix Biopharma in a research note on Friday, July 17th. Citigroup began coverage on shares of Immix Biopharma in a research report on Thursday, June 18th. They set a “buy” rating for the company. Lifesci Capital initiated coverage on shares of Immix Biopharma in a report on Wednesday, June 17th. They issued an “outperform” rating and a $19.00 price target on the stock. Needham & Company LLC assumed coverage on shares of Immix Biopharma in a research report on Wednesday, July 22nd. They issued a “buy” rating and a $21.00 price target on the stock. Finally, HC Wainwright raised their price objective on shares of Immix Biopharma from $20.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $21.29.

Immix Biopharma Stock Up 13.4%

Shares of NASDAQ:IMMX opened at $11.49 on Wednesday. Immix Biopharma, Inc. has a 52-week low of $1.94 and a 52-week high of $12.14. The stock’s fifty day simple moving average is $9.46 and its 200-day simple moving average is $8.94. The company has a market capitalization of $625.17 million, a P/E ratio of -13.06 and a beta of 0.11.

Immix Biopharma (NASDAQ:IMMX) last posted its quarterly earnings data on Friday, August 7th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). On average, sell-side analysts anticipate that Immix Biopharma, Inc. will post -0.69 earnings per share for the current year.

Immix Biopharma Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.